New eczema drug takes on dupixent in major trial
NCT ID NCT07386743
First seen Feb 04, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tests a new medicine called GS101 against the standard treatment Dupixent for people with moderate-to-severe atopic dermatitis (eczema). About 572 adults aged 18 to 75 will receive either GS101 or Dupixent injections for up to a year. The main goal is to see if GS101 can reduce eczema severity by at least 75% after 16 weeks, similar to Dupixent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.